References
-
1
Agency for Toxic Substances and
Disease Registry. Toxicological profile for
perfluoroalkyls; 2021. Accessed April 27, 2023.
https://www.atsdr.cdc.gov/ToxProfiles/tp200.pdf . - 2 Yamashita N, et al. Perfluorinated acids as novel chemical tracers of global circulation of ocean waters. Chemosphere. 2008; 70(7): 1247–1255. DOI: 10.1016/j.chemosphere.2007.07.079
- 3 Tao L, et al. Perfluorooctanesulfonate and related fluorochemicals in albatrosses, elephant seals, penguins, and polar skuas from the Southern Ocean. Environ Sci Technol. 2006; 40(24): 7642–7648. DOI: 10.1021/es061513u
- 4 Kwiatkowski CF AD, et al. Scientific basis for managing PFAS as a chemical class. Environ Sci Technol Lett. 2020 Aug 11; 7(8): 532–543. DOI: 10.1021/acs.estlett.0c00255
- 5 Calafat AM, et al. Polyfluoroalkyl chemicals in the US population: data from the National Health and Nutrition Examination Survey (NHANES) 2003–2004 and comparisons with NHANES 1999–2000. Environ Health Perspect. 2007; 115(11): 1596–1602. DOI: 10.1289/ehp.10598
- 6 Bjerregaard-Olesen C, et al. Maternal serum concentrations of perfluoroalkyl acids in five international birth cohorts. Int J Hyg Environ Health. 2017; 220(2A): 86–93. DOI: 10.1016/j.ijheh.2016.12.005
- 7 Padula AM, et al. Birth outcomes in relation to prenatal exposure to per- and polyfluoroalkyl substances and stress in the environmental influences on child health outcomes (ECHO) program. Environ Health Perspect. 2023; 131(3): 1–11. DOI: 10.1289/EHP10723
-
8
National Toxicology
Program, et al. Monograph on immunotoxicity associated with
exposure to perfluorooctanoic acid (PFOA) and perfluorooctane sulfonate
(PFOS); 2016.
http://ntp.niehs.nih.gov/ntp/ohat/pfoa_pfos/pfoa_pfosmonograph_508.pdf . -
9
U.S. Environmental Protection
Agency. PFAS master list of PFAS substances (Version
2); 2021.
https://comptox.epa.gov/dashboard/chemical_lists/PFASMASTER . -
10
U.S. Environmental Protection
Agency Science Advisory Board (SAB). Review of EPA’s
analyses to support EPA’s national primary drinking water rulemaking
for PFAS FINAL REPORT; 2022.
https://sab.epa.gov/ords/sab/f?p=100:18:16490947993:::RP,18:P18_ID:2601 . - 11 Rogers RD, et al. Advancing per- and polyfluoroalkyl substances (PFAS) research: an overview of ATSDR and NCEH activities and recommendations. J Expo Sci Environ Epidemiol. 2021; 31(6): 961–971. DOI: 10.1038/s41370-021-00316-6
- 12 National Academies of Sciences, Engineering, and Medicine. Guidance on PFAS exposure, testing, and clinical follow-up; 2022. DOI: 10.17226/26156
- 13 Tepper LB. Teflon. N Engl J Med. 1962; 267(7): 349–350. DOI: 10.1056/NEJM196208162670709
-
14
Chemours.com.
Teflon™. Accessed November 20, 2020.
https://www.teflon.com/en/news-events/history#:~:text=The%20first%20Teflon%E2%84%A2%20products,and%20product%20innovations%20quickly%20followed . - 15 Bilott R. Exposure: Poisoned water, corporate greed, and one lawyer’s twenty-year battle against DuPont. Atria Books; 2020.
-
16
U.S. Environmental Protection
Agency. EPA settles PFOA case against DuPont for largest
environmental administrative penalty in agency history;
2005.
https://www.epa.gov/enforcement/reference-news-release-epa-settles-pfoa-case-against-dupont-largest-environmental . -
17
Environmental Working
Group. For DuPont, $1B a year rides on
teflon.
https://www.ewg.org/news-insights/news/dupont-1b-year-rides-teflon . -
18
Hogue
C.
U.S. class-action case targets nine PFAS makers . C&EN2018. -
19
Hardwick et al.
Hardwick v. 3M Company et al, No. 2:2018cv01185 –
Document 166 (S.D. Ohio 2020). Justia.
2020.
https://law.justia.com/cases/federal/district-courts/ohio/ohsdce/2:2018cv01185/217689/166/ . -
20
Fletcher
T, et al. C8 probable link
reports; 2012.
http://www.c8sciencepanel.org/prob_link.html . - 21 Frisbee SJ, et al. The C8 health project: design, methods, and participants. Environ Health Perspect. 2009; 117(12): 1873–82. DOI: 10.1289/ehp.0800379
-
22
Nair
A. DuPont settles
lawsuits over leak of chemical used to make Teflon.
Reuters. February
13, 2017.
https://www.reuters.com/article/us-du-pont-lawsuit-west-virginia/dupont-settles-lawsuits-over-leak-of-chemical-used-to-make-teflon-idUSKBN15S18U . - 23 Johnson PI, et al. The Navigation Guide—evidence-based medicine meets environmental health: systematic review of human evidence for PFOA effects on fetal growth. Environ Health Perspect. 2014; 122(10): 1028–1039. DOI: 10.1289/ehp.1307893
-
24
National Toxicology
Program. Systematic review of immunotoxicity associated
with exposure to PFOA or PFOS; 2016.
https://ntp.niehs.nih.gov/whatwestudy/assessments/noncancer/completed/pfoa/index.html . -
25
Ding
N. Perfluoroalkyl and
polyfluoroalkyl substances and women’s health: A possible etiology for
earlier menopause and accelerated reproductive aging;
2020.
https://deepblue.lib.umich.edu/handle/2027.42/155094 . -
26
U.S. Environmental Protection
Agency. Lifetime health advisories and health effects
support documents for perfluorooctanoic acid and perfluorooctane
sulfonate; 2016. May
25.
https://www.govinfo.gov/content/pkg/FR-2016-05-25/pdf/2016-12361.pdf . - 27 Steenland K, et al. Review: Evolution of evidence on PFOA and health following the assessments of the C8 Science Panel. Environ Int. 2020; 145: 1–12. DOI: 10.1016/j.envint.2020.106125
- 28 Fenton SE, et al. Per-and polyfluoroalkyl substance toxicity and human health review: Current state of knowledge and strategies for informing future research. Environ Toxicol Chem. 2020; 40(3): 606–630. DOI: 10.1002/etc.4890
-
29
Walker
B, et al.
Teflon chemical harmful at smallest doses . Environmental Working Group. Accessed November 23, 2020.https://www.ewg.org/research/teflon-chemical-harmful-at-smallest-doses . - 30 Pontius F. Regulation of perfluorooctanoic acid (PFOA) and perfluorooctane sulfonic acid (PFOS) in drinking water: A comprehensive review. Water. 2019; 11(2003): 1–27. DOI: 10.3390/w11102003
-
31
U. S. Environmental Protection
Agency (EPA). Per- and Polyfluoroalkyl substances
(PFAS): Proposed PFAS national primary drinking water
regulation. Accessed April 27, 2023.
https://www.epa.gov/sdwa/and-polyfluoroalkyl-substances-pfas . -
32
Ross
D. Rainwater in
parts of US contains high levels of PFAS chemical, says
study. The Guardian. Dec
17.
https://www.theguardian.com/environment/2019/dec/17/rainwater-pfas-us-potentially-toxic-levels-study . -
33
Evans
S, et al. PFAS
contamination of drinking water far more prevalent than previously
reported; 2020. Jan
22.
https://www.ewg.org/research/national-pfas-testing/ . - 34 Grandjean P, et al. Immunotoxicity of perfluorinated alkylates: calculation of benchmark doses based on serum concentrations in children. Environ Health. 2013; 12(1): 1–7. DOI: 10.1186/1476-069X-12-35
-
35
U.S. Environmental Protection
Agency.
Addition of certain PFAS to the TRI by the National Defense Authorization Act . United States Environmental Protection Agency. Accessed November 20 2020.https://www.epa.gov/toxics-release-inventory-tri-program/addition-certain-pfas-tri-national-defense-authorization-act . - 36 Cotruvo JA, et al. EPA’s unprecedented interim drinking water health advisories for PFOA and PFOS. Groundwater. 2023; 1–3. DOI: 10.1111/gwat.13303
- 37 White J, et al. Corporate manipulation of research: Strategies are similar across five industries. Stan L & Pol’y Rev. 2010; 28(1): 1–2.
- 38 Hendlin YH, et al. The pharmaceuticalization of the tobacco industry. Ann Intern Med. 2017; 167(4): 278–280. DOI: 10.7326/M17-0759
- 39 Apollonio DE, et al. The creation of industry front groups: the tobacco industry and “get government off our back”. Am J Public Health. 2007; 97(3): 419–27. DOI: 10.2105/AJPH.2005.081117
- 40 Bero L. Implications of the tobacco industry documents for public health and policy. Annu Rev Public Health. 2003; 24: 267–88. DOI: 10.1146/annurev.publhealth.24.100901.140813
- 41 Wiist WH. The corporate play book, health, and democracy: the snack food and beverage industry’s tactics in context. Sick societies: Responding to the global challenge of chronic disease. 2011; 204–216.
- 42 Michaels D. The triumph of doubt: dark money and the science of deception. Oxford University Press; 2020.
- 43 Buse K, et al. Healthy people and healthy profits? Elaborating a conceptual framework for governing the commercial determinants of non-communicable diseases and identifying options for reducing risk exposure. Globalization and health. 2017; 13(1): 1–12. DOI: 10.1186/s12992-017-0255-3
- 44 Kickbusch I, et al. The commercial determinants of health. The Lancet Global Health. 2016; 4(12): e895–e896. DOI: 10.1016/S2214-109X(16)30217-0
- 45 Lee K, et al. Understanding structure and agency as commercial determinants of health: Comment on” How neoliberalism is shaping the supply of unhealthy commodities and what this means for NCD prevention”. International Journal of Health Policy and Management. 2020; 9(7): 315–318. DOI: 10.15171/ijhpm.2019.127
-
46
UCSF Library.
Industry documents library: About . University of California.https://www.industrydocuments.ucsf.edu/about/overview/ . - 47 Malone RE, et al. Tobacco industry documents: Treasure trove or quagmire? Tob Control. 2000; 9(3): 334–338. DOI: 10.1136/tc.9.3.334
- 48 Bero LA. Tobacco industry manipulation of research. Public Health Rep. 2005; 120(2): 200–8. DOI: 10.1177/003335490512000215
- 49 Hastings G, et al. A day in the life of an advertising man: Review of internal documents from the UK tobacco industry’s principal advertising agencies. BMJ. 2000; 321(7257): 366–371. DOI: 10.1136/bmj.321.7257.366
- 50 O’Sullivan B, et al. Eyes on the prize: Transnational tobacco companies in China 1976–1997. Tob Control. 2000; 9(3): 292–302. DOI: 10.1136/tc.9.3.292
- 51 Soechtig S, et al. The devil we know; 2018.
- 52 Fabbri A, et al. The influence of industry sponsorship on the research agenda: A scoping review. Am J Public Health. 2018; 108(11): e9–e16. DOI: 10.2105/AJPH.2018.304677
- 53 Lau C, et al. Perfluoroalkyl acids: A review of monitoring and toxicological findings. Toxicol Sci. 2007; 99(2): 366–394. DOI: 10.1093/toxsci/kfm128
- 54 Harris DK. Some hazards in the manufacture and use of plastics. Occup Environ Med. 1959; 16(3): 221–229. DOI: 10.1136/oem.16.3.221
- 55 Kóster A, et al. Toxisches Lungenödem durch Teflondämpfe [Toxic pulmonary edema due to teflon vapors]. German. Wien Med Wochenschr. 1978; 128(14).
- 56 Sherwood RJ. The hazards of Fluon (Polytetrafluoroethylene). Occup Med. 1955; 5(1): 10–12. DOI: 10.1093/occmed/5.1.10
- 57 Lewis CE, et al. An epidemic of polymer-fume fever. JAMA. 1965; 191(5): 375–378. DOI: 10.1001/jama.1965.03080050021005
- 58 Robbins J, et al. Pulmonary edema from Teflon fumes. N Engl J Med. 1964; 271: 360–361. DOI: 10.1056/NEJM196408132710708
-
59
Mack
GJ. Toxicity of
decomposition products of “Teflon”. Can
Med Assoc J. 1961;
85(17):
955–955.
https://pubmed.ncbi.nlm.nih.gov/20326927/ . -
60
Mastromatteo
E. Toxicity of
decomposition products of “Teflon”. Can
Med Assoc J. 1961;
85(25):
1357–1357.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1848628/ . -
61
Zapp,
JA
Jr. . Toxic and health effects of plastics and resins. Archives of Environmental Health: An International Journal. 1962; 4(3): 335–346. DOI: 10.1080/00039896.1962.10663162 -
62
Mack
GJ. Toxicity of
decomposition products of “Teflon”. Can
Med Assoc J. 1961;
85(25):
1358–1358.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1848625/ . -
63
Abbey
DR. Toxicity of
decomposition products of “Teflon”. Can
Med Assoc J. 1961;
85(25):
1357–1358. PMC1848634.
https://pubmed.ncbi.nlm.nih.gov/20326977/ . - 64 Griffith FD, et al. Exposure of Japanese quail and parakeets to the pyrolysis products of fry pans coated with Teflon® and common cooking oils. Am Ind Hyg Assoc J. 1973; 34(4): 176–178. DOI: 10.1080/0002889738506828
-
65
DuPont™ Teflon®
nonstick coating systems: still making history after half a century of
leadership. DuPont EMEA Media
Center; 2011.
https://us.vocuspr.com/Newsroom/MultiQuery.aspx?SiteName=DupontEMEA&Entity=PRAsset&SF_PRAsset_PRAssetID_EQ=119529&XSL=NewsRelease&IncludeChildren=True&Lang=English . - 66 Ubel F, et al. Health status of plant workers exposed to fluorochemicals – a preliminary report. Am Ind Hyg Assoc J. 1980; 41(8): 584–589. DOI: 10.1080/15298668091425310
- 67 Griffith F, et al. Animal toxicity studies with ammonium perfluorooctanoate. Am Ind Hyg Assoc. 1980; 41: 576–583. DOI: 10.1080/15298668091425301
- 68 Kennedy G. Dermal toxicity of ammonium perfluorooctanoate. Toxicol Appl Pharmacol. 1985; 81: 348–355. DOI: 10.1016/0041-008X(85)90172-3
- 69 Kennedy G, et al. Inhalation toxicity of ammonium perfluoroctanoate. Food Chem Toxic. 1986; 24: 1325–1329. DOI: 10.1016/0278-6915(86)90066-9
- 70 Pastoor T, et al. Biochemical and morphological studies of ammonium perfluorooctanoate-induced hepatomegaly and peroxisome proliferation. Exp Mol Pathol. 1987; 47: 98–109. DOI: 10.1016/0014-4800(87)90011-6
- 71 Van Rafelghem M, et al. Patholgoical and hepatic ultrastructural effects of a single dose of perfluoro-n-decanoic acid in the rat, hamster, mouse and guinea pig. Fundam Appl Toxicol. 1987; 9522–540. DOI: 10.1093/toxsci/9.3.522
- 72 Takagi A, et al. Short-term exposure to the peroxisome proliferators, perfluoooctanoic acid and perfluorodecanoic acid, causes significant increases of X-hydroxydeoxyguanosine in liver DNA of rats. Cancer Lett. 1991; 57: 55–60. DOI: 10.1016/0304-3835(91)90063-N
- 73 Just W, et al. Biochemical effects and zonal heterogeneity of peroxisome proliferation induced by perfluorocarboxylic acids in rat liver. Hepatology. 1989; 9570–58. DOI: 10.1002/hep.1840090411
- 74 Keller B, et al. Several nongenotoxic carcinogens uncouple mitochondria1 oxidative phosphorylation. Biochim Biophys Acta. 1992; 102: 237–244. DOI: 10.1016/0005-2728(92)90105-B
- 75 Haughom B, et al. The mechanism underlying the hypolipemic effect of perfluorooctanoic acid (PFOA), perfluorooctane sulphonic acid (PFOSA) and clofibric acid. Biochim Biophys Acta. 1992; 128: 65–12. DOI: 10.1016/0005-2760(92)90258-W
- 76 Sohlenius K, et al. The effects of perfluoro-octanoic acid on hepatic peroxisome proliferation and related parameters show no sex-related differences in mice. Biochem Toxicol. 1992; 285: 779–783. DOI: 10.1042/bj2850779
- 77 Ylinen M, et al. Disposition of perfluorooctanoic acid in the rat after single and subchronic administration. Bull Environ Contam Toxicol. 1990; 44: 46–53. DOI: 10.1007/BF01702360
- 78 Gilliland F, et al. Mortality among employees in a PFOA production plant. J Occup Med. 1993; 35: 950–954. DOI: 10.1097/00043764-199309000-00020
- 79 Gilliland FD, et al. Serum perfluorooctanoic acid and hepatic enzymes, lipoproteins, and cholesterol: A study of occupationally exposed men. Am J Ind Med. 1996; 29(5): 560–568. DOI: 10.1002/(SICI)1097-0274(199605)29:5<;560::AID-AJIM17>3.0.CO;2-Z
- 80 Lau C, et al. Exposure to perfluorooctane sulfonate during pregnancy in rat and mouse. II: postnatal evaluation. Toxicol Sci. 2003; 74(2): 382–92. DOI: 10.1093/toxsci/kfg122
- 81 Thibodeaux JR, et al. Exposure to perfluorooctane sulfonate during pregnancy in rat and mouse. I: maternal and prenatal evaluations. Toxicol Sci. 2003; 74(2): 369–81. DOI: 10.1093/toxsci/kfg121
- 82 Lau C, et al. The developmental toxicity of perfluoroalkyl acids and their derivatives. Toxicology and applied pharmacology. 2004; 198(2): 231–241. DOI: 10.1016/j.taap.2003.11.031
- 83 3M Company. Environmental and health assessment of perfluorooctanesulfonate and its salts. US EPA Administrative Record. AR-226-1486; 2003.
- 84 3M Company. A 28-day oral (gavage) toxicity study of T-7485 in Sprague-Dawley rats Study no. 132-007; 2005.
- 85 DuPont. Epidemiology surveillance report: Cancer incidence for Washington Works site 1959–2001. US EPA Administrative Record, AR-226-1307-6; 2003.
-
86
DuPont de Nemours, et
al. Ammonium Perfluorooctanoate: Phase II. Retrospective cohort
mortality analyses related to a serum biomarker of exposure in a polymer
production plant. Report No 8EHQ-0381-0394. 2007;
EPA National Libary Catalog.
https://cfpub.epa.gov/ols/catalog/advanced_full_record.cfm?&FIELD1=SUBJECT&INPUT1=Polymer&TYPE1=EXACT&LOGIC1=AND&COLL=&SORT_TYPE=MTIC&item_count=10 . -
87
Bower
W. C8 exposure –
medical surveillance; 1978. (yypw0228).
https://www.industrydocuments.ucsf.edu/docs/yypw0228 . -
88
Fayerweather WE.
Liver study of Washington Works employees exposed to C8: Results of
blood biochemistry testing; 1981. (hypw0228).
https://www.industrydocuments.ucsf.edu/docs/hypw0228 . -
89
Arenson
G. Toxicity of Teflon
dispersing agents; 1961. (snpw0228).
https://www.industrydocuments.ucsf.edu/docs/#id=snpw0228 . -
90
Hilton
W, et al. Request for
toxicological information – “Teflon” division
chemicals; 1970.(knpw0228).
https://www.industrydocuments.ucsf.edu/docs/#id=knpw0228 . -
91
Snyder
S, et al. Haskell
Laboratory Report on Apfo/C8. PFAS Collection, UCSF
Industry Documents Library; 1979. (hppw0228).
https://www.industrydocuments.ucsf.edu/docs/hppw0228 . -
92
DuPont. C-8
blood sampling results; 1981. (xnpw0228).
https://www.industrydocuments.ucsf.edu/docs/#id=xnpw0228 . -
93
Raines
J, et al. Ammonium
Perfluorooctanoate – C8 – rangefinder Study;
1981. (nnpw0228).
https://www.industrydocuments.ucsf.edu/docs/#id=nnpw0228 . -
94
Smith
H. Agenda: C8 review April
26, 1990; 1990. (xypw0228).
https://www.industrydocuments.ucsf.edu/docs/#id=xypw0228 . -
95
Boone
S, et al. C8 Ammonium
Perfluorooctanoate Fluorosurfactant strategies and plans;
1994.(typw0228).
https://www.industrydocuments.ucsf.edu/docs/#id=typw0228 . -
96
Steiner
C. C8 communications
meeting – outline, talk and charts; 1980.
(nypw0228).
https://www.industrydocuments.ucsf.edu/docs/#id=nypw0228 . -
97
Ingalls
R, et al. C8
Perfluorooctonate – employee communication package;
1981. (kypw0228).
https://www.industrydocuments.ucsf.edu/docs/#id=kypw0228 . -
98
Eaton
M, et al. Standby press
release – public notification C8; 1991.
(rypw0228).
https://www.industrydocuments.ucsf.edu/docs/#id=rypw0228 . -
99
Reilly
B. Email from Bernard J
Reilly re: lawyer for farmer going to the press to settle;
2000. (lypw0228).
https://www.industrydocuments.ucsf.edu/docs/#id=lypw0228 . -
100
Stalnecker
S, et al. Urgent email re:
EPA; 2006. (jppw0228).
https://www.industrydocuments.ucsf.edu/docs/#id=jppw0228 . -
101
DuPont. C8
background sheet; 1991. (yppw0228).
https://www.industrydocuments.ucsf.edu/docs/#id=yppw0228 . -
102
Cox
JM. Letter to Lubeck Public
Service District customers re: the annual water quality report on July 1,
2000. PFAS Collection, UCSF Industry Documents Library;
2000. (qnpw0228).
https://www.industrydocuments.ucsf.edu/docs/#id=qnpw0228 . -
103
E.I. du Pont de Nemours &
Company.. Haskell Laboratory for Toxicology and
Industrial Medicine Records. Archival Collections at
Hagley Museum & Library Accession: 2739, 1930–2013.
https://hagley-aspace-pdf.s3.amazonaws.com/2739.pdf . -
104
DuPont. DuPont
Haskell Lab document w C8 molecule chain. PFAS
Collection, UCSF Industry Documents Library;
1988. (mppw0228).
https://www.industrydocuments.ucsf.edu/docs/#id=mppw0228 . - 105 Reilly B. Email from Bernard J Reilly re: 3M announcment; 2000.
- 106 Wilson MP, et al. Toward a new US chemicals policy: rebuilding the foundation to advance new science, green chemistry, and environmental health. Environ Health Perspect. 2009; 117(8): 1202–1209. DOI: 10.1289/ehp.0800404
- 107 Vogel SA, et al. Why the toxic substances control act needs an overhaul, and how to strengthen oversight of chemicals in the interim. Health Aff (Millwood). 2011; 30(5): 898–905. DOI: 10.1377/hlthaff.2011.0211
- 108 Silbergeld EK, et al. Regulating chemicals: law, science, and the unbearable burdens of regulation. Annu Rev Public Health. 2015; 36: 175–191. DOI: 10.1146/annurev-publhealth-031914-122654
- 109 Richter L, et al. Producing ignorance through regulatory structure: The case of per-and polyfluoroalkyl substances (PFAS). Sociological Perspectives. 2020; 64(4): 631–656. DOI: 10.1177/0731121420964827
- 110 Michaels D. Doubt is their product: How industry’s assult on science threatens your health. 1st ed. Oxford University Press; 2008.
-
111
International Network for
Epidemiology in Policy. Conflict-of-Interest and Disclosure
in Epidemiology; 2020.
https://epidemiologyinpolicy.org/coi-d-position-statement . - 112 Bero L. Ten tips for spotting industry involvement in science policy. Tob Control. 2019; 28(1): 1–2. DOI: 10.1136/tobaccocontrol-2018-054386